HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up.
The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.
Moreira
Regina Célia
RC
Serviço de Virologia, Instituto Adolfo Lutz, São Paulo, SP, Brasil. regina.moreira7@gmail.com
Deguti
Marta Mitiko
MM
Lemos
Marcilio Figueiredo
MF
Saraceni
Cláudia Patara
CP
Oba
Isabel Takano
IT
Spina
Angela Maria Miranda
AM
Nascimento-Lima
Alessandra Stilhano
AS
Fares
Jorge
J
Azevedo
Raymundo Soares
RS
Gomes-Gouvêa
Michele Soares
MS
Carrilho
Flair José
FJ
Pinho
João Renato Rebello
JR
D015415:Biomarkers / Q000097:blood; D001938:Brazil / Q000453:epidemiology; D004279:DNA, Viral / Q000097:blood; D004812:Epidemiologic Methods; D006509:Hepatitis B / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D016133:Polymerase Chain Reaction; D006435:Renal Dialysis
D015415:Biomarkers; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens